Catalyst
Slingshot members are tracking this event:
U.S. Centers for Medicare & Medicaid Services (CMS) Establishes Specific Reimbursement Code for Teva and Eagle's (EGRX) BENDEKA, a Treatment for Chronic Lymphocytic Leukemia and Certain Patients with Indolent B-cell Non-Hodgkin Lymphoma
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 02, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
U.s. Centers For Medicare & Medicaid Services, Cms, Reimbursement Code, Bendeka, Chronic Lymphocytic Leukemia, Indolent B-cell Non-hodgkin Lymphoma
